Author:
Taşlı Neslihan Pakize,Gönen Zeynep Burçin,Kırbaş Oğuz Kaan,Gökdemir Nur Seda,Bozkurt Batuhan Turhan,Bayrakcı Buse,Sağraç Derya,Taşkan Ezgi,Demir Sevda,Ekimci Gürcan Nur,Bayındır Bilgiç Melike,Bayrak Ömer Faruk,Yetişkin Hazel,Kaplan Büşra,Pavel Shaikh Terkıs Islam,Dinç Gökçen,Serhatlı Müge,Çakırca Gamze,Eken Ahmet,Aslan Vedat,Yay Mehmet,Karakukcu Musa,Unal Ekrem,Gül Fethi,Basaran Kemal Erdem,Ozkul Yusuf,Şahin Fikrettin,Jones Olcay Y.,Tekin Şaban,Özdarendeli Aykut,Cetin Mustafa
Abstract
The scale of the COVID-19 pandemic forced urgent measures for the development of new therapeutics. One of these strategies is the use of convalescent plasma (CP) as a conventional source for passive immunity. Recently, there has been interest in CP-derived exosomes. In this report, we present a structural, biochemical, and biological characterization of our proprietary product, convalescent human immune plasma-derived exosome (ChipEXO), following the guidelines set forth by the Turkish Ministry of Health and the Turkish Red Crescent, the Good Manufacturing Practice, the International Society for Extracellular Vesicles, and the Gene Ontology Consortium. The data support the safety and efficacy of this product against SARS-CoV-2 infections in preclinical models.
Subject
Immunology,Immunology and Allergy
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献